EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Economic burden of sickle cell disease in Australia

Steve Nwokeocha, Helen E Haysom, Cameron Wellard, Tracy Roberts, Mwayi Kachapila, Melissa Chee, Dennis Petrie, Zoe K McQuilten, Neil Waters, Anthea Greenway, Kylie Mason, Anna Nelson iD und 5 weitere

Internal Medicine Journal · 2025

DOI: 10.1111/imj.70092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Steve Nwokeocha und 16 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics Unit, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Cost of Illness, Health Care Costs. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Turing Scheme, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sickle cell disease (SCD) is an inherited condition that impairs red blood cell function, posing a substantial health burden on patients. As the prevalence of SCD in Australia rises due to migration, discussions surrounding treatment and management strategies are becoming more prominent.

Aims

Australia lacks a dedicated study on the prevalence and economic implications of SCD. In this study, we estimate the economic burden of SCD in Australia from the perspective of the Australian healthcare system.

Methods

We performed a cost‐of‐illness study by using a bottom‐up approach to estimate resource use per patient from a national registry with unit costs from national sources, and a top‐down estimate of the prevalence of SCD in Australia using stratification by ancestry.

Results

We estimated the prevalence of SCD in Australia in 2021 to be 8485 patients, the cost per patient per year to be AU$13 975 and the total cost to the Australian healthcare system to be approximately AU$119 million per year. Factors influencing costs were age, interventions and frequency of hospital visits for vaso‐occlusive crises. Prevalence had the greatest influence on results in the sensitivity analysis.

Conclusions

While the estimated prevalence of SCD in Australia resulted in a relatively small total cost, the per patient annual cost of SCD remains high. This cost of SCD is anticipated to increase alongside migration and improved treatment. There are policies that could enhance patients' quality of life, thereby mitigating both economic and health burdens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellCost of IllnessHealth Care CostsHumansAustraliaAdultMaleFemaleMiddle AgedAdolescentYoung AdultPrevalenceChildChild, PreschoolAgedRegistriesInfant

Stichwörter der Autor:innen

cost of illnessprevalencesickle cell disease

Autor:innen und Institutionen

  • Health Economics Unit, University of Birmingham, Birmingham, UK.
  • Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • Centre for Health Economics, Monash Business School, Monash University, Melbourne, Victoria, Australia.
  • Department of Clinical Haematology, Monash Health, Melbourne, Victoria, Australia.
  • Department of Clinical Haematology, Royal Children's Hospital, Melbourne, Victoria, Australia.
  • Department of Haematology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.

ORCID-Profile: Anna Nelson, P Joy Ho, Adam Irving

Förderung

  • Turing Scheme
  • National Health and Medical Research Council

Zitieren

APA

Nwokeocha, S., Haysom, H. E., Wellard, C., Roberts, T., Kachapila, M., Chee, M., Petrie, D., McQuilten, Z. K., Waters, N., Greenway, A., Mason, K., Nelson, A., Kaplan, Z., Ho, P. J., Wood, E. M., Irving, A., & Australian Haemoglobinopathy Registry (2025). Economic burden of sickle cell disease in Australia. Internal Medicine Journal. https://doi.org/10.1111/imj.70092

Vancouver

Nwokeocha S, Haysom HE, Wellard C, Roberts T, Kachapila M, Chee M, et al. Economic burden of sickle cell disease in Australia. Internal Medicine Journal. 2025. doi:10.1111/imj.70092

BibTeX
@article{Nwokeocha2025,
  author = {Nwokeocha, Steve and Haysom, Helen E and Wellard, Cameron and Roberts, Tracy and Kachapila, Mwayi and Chee, Melissa and Petrie, Dennis and McQuilten, Zoe K and Waters, Neil and Greenway, Anthea and Mason, Kylie and Nelson, Anna and Kaplan, Zane and Ho, P Joy and Wood, Erica M and Irving, Adam and Australian Haemoglobinopathy Registry, Australian Haemoglobinopathy Registry},
  title = {Economic burden of sickle cell disease in Australia},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.70092}
}
Kostenlos starten →